Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Learn More

Research & Development

Product Pipeline

Explore

Targeted Approach To

Rare Diseases

Read More

News & Events

September 29, 2017
Proteus Syndrome Phase 1 Data Presentation
Watch Video »
June 25, 2019
ArQule Announces Pricing of $90 Million Public Offering of Common Stock
Read More »
June 27, 2019
ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Read More »

More News & Events »

arqule

© Copyright ArQule. All rights reserved. Terms of Use.